Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Stealth BioTherapeutics Announces Acceptance of Late-Breaking Clinical Trial Poster at American Society of Nephrology Kidney Week 2016

Stealth BioTherapeutics
Posted on: 07 Nov 16

PR Newswire

BOSTON, Nov. 7, 2016

BOSTON, Nov. 7, 2016 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that the abstract, "Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis" has been accepted as a late-breaking clinical trial poster at the American Society of Nephrology (ASN) Kidney Week 2016 taking place in Chicago, November 15-20, 2016.

"The EVOLVE trial underscores our commitment to our cardiorenal program," said Stealth's Chief Executive Officer Reenie McCarthy. "We are pleased to present the details of these results both in the context of our three ongoing Phase 2 heart failure studies, as well as to inform our approach to other diseases of aging in which mitochondrial dysfunction is a contributing factor."

EVOLVE was a double-blind, placebo-controlled study that evaluated 14 patients ages 40 to 80 with chronic kidney disease (CKD) at risk of acute kidney injury (AKI). The primary endpoint was change in kidney function, and the secondary endpoint was a change in renal blood flow and cortical perfusion.

Additional information on the late-breaking clinical trial poster presentation:

"Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) during Stent Revascularization in Patients with Atherosclerotic Renal Artery Stenosis"
Presented by: Ahmed Saad, M.D., Sandra Herrmann, M.D., Lilach O. Lerman, M.D., Ph.D., and principal investigator, Stephen C. Textor, M.D.
Date & Time of Poster Presentation: Friday, November 18 from 10:00 A.M. to 12:00 P.M. CT
Location: Exhibit Halls F1/F2
Poster Number: FR-PO1124

About Elamipretide
Stealth's lead candidate, elamipretide, is an investigational drug with the potential to modify disease by preserving energetics and restoring normal energy production in mitochondria, while decreasing oxidative stress. The energetics from mitochondria maintain healthy physiology and prevent disease. This mitochondria-targeted candidate is being developed for both rare diseases and common diseases of aging.

Stealth BioTherapeutics: Leading Mitochondrial Medicine
Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both rare diseases and common diseases of aging. Stealth's clinical development program is focused along several core therapeutic areas, including primary mitochondrial diseases, cardiorenal diseases and ophthalmic disorders. More information regarding Stealth and its pipeline is available at

Media Relations
dna Communications
Kate Contreras, 617-520-7088 

Investor Relations
Stern IR
Beth DelGiacco, 212-362-1200

Logo -

To view the original version on PR Newswire, visit:

SOURCE Stealth BioTherapeutics

PR Newswire

Last updated on: 07/11/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.